Managers / Q1 2020 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Reported Value
$253M
Q1 2020
Positions
40
Filings on Record
30
2019–present window
Filed
May 15, 2020
original filing
Summary
Sivik Global Healthcare LLC reported $253M in U.S.-listed holdings across 40 positions for Q1 2020.
Its largest position, COR, represents 5.0% of the portfolio.
Compared with Q4 2019, the fund opened 10 new positions and exited 22.
Portfolio Metrics
Turnover
+40.3%
vs prior filed quarter
Top-10 Concentration
+40.7%
share of reported value
Largest Position
+5.0%
Humana
New / Exited
10 / 22
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 86.6% · $219M
- ADR · 13.4% · $34M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CORHumana Inc | NEW | +40.0K | 40.0K | +$13M | $13M |
| MCKThermo Fisher Scientific Inc | NEW | +32.5K | 32.5K | +$9M | $9M |
| NVOBoston Scientific Corp | NEW | +250.0K | 250.0K | +$8M | $8M |
| EHCVertex Pharmaceuticals Inc | NEW | +32.5K | 32.5K | +$8M | $8M |
| CAHBaxter International Inc | NEW | +90.0K | 90.0K | +$7M | $7M |
| Novo Nordisk A/S | NEW | +100.0K | 100.0K | +$6M | $6M |
| PRGOAbbVie Inc | NEW | +65.0K | 65.0K | +$5M | $5M |
| S24Catalent Inc | NEW | +80.0K | 80.0K | +$4M | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2020
40 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CORHumana Inchistory → | Cash Securities | 4.96% | $13M | 40.0K |
| 2 | SNNHCA Healthcare Inchistory → | Cash Securities | 4.79% | $12M | 135.2K |
| 3 | INCYUniversal Health Services Inchistory → | Cash Securities | 4.50% | $11M | 115.0K |
| 4 | UNHUnitedHealth Group Inchistory → | Cash Securities | 4.18% | $11M | 42.5K |
| 5 | BMYCentene Corphistory → | Cash Securities | 4.10% | $10M | 175.0K |
| 6 | DHRAmerisourceBergen Corphistory → | Cash Securities | 4.02% | $10M | 115.0K |
| 7 | AZNNMcKesson Corphistory → | Cash Securities | 4.00% | $10M | 75.0K |
| 8 | MCKThermo Fisher Scientific Inchistory → | Cash Securities | 3.64% | $9M | 32.5K |
| 9 | CNCCardinal Health Inchistory → | Cash Securities | 3.31% | $8M | 175.0K |
| 10 | NVOBoston Scientific Corphistory → | Cash Securities | 3.22% | $8M | 250.0K |
| 11 | BMYBristol-Myers Squibb Cohistory → | Cash Securities | 3.19% | $8M | 145.0K |
| 12 | EHCVertex Pharmaceuticals Inchistory → | Cash Securities | 3.05% | $8M | 32.5K |
| 13 | HCAAbbott Laboratorieshistory → | Cash Securities | 2.96% | $7M | 95.0K |
| 14 | CIStryker Corphistory → | Cash Securities | 2.96% | $7M | 45.0K |
| 15 | CAHBaxter International Inchistory → | Cash Securities | 2.88% | $7M | 90.0K |
| 16 | ISRGTenet Healthcare Corphistory → | Cash Securities | 2.76% | $7M | 485.5K |
| 17 | SYKEli Lilly and Cohistory → | Cash Securities | 2.74% | $7M | 50.0K |
| 18 | HUMDanaher Corphistory → | Cash Securities | 2.73% | $7M | 50.0K |
| 19 | UHSHill-Rom Holdings Inchistory → | Cash Securities | 2.58% | $7M | 65.0K |
| 20 | BIIBBiogen Inchistory → | Cash Securities | 2.50% | $6M | 20.0K |
| 21 | Novo Nordisk A/S | Cash Securities | 2.38% | $6M | 100.0K |
| 22 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 2.33% | $6M | 70.0K |
| 23 | MRKEncompass Health Corphistory → | Cash Securities | 2.02% | $5M | 80.0K |
| 24 | ABTMerck & Co Inchistory → | Cash Securities | 1.97% | $5M | 65.0K |
| 25 | PRGOAbbVie Inchistory → | Cash Securities | 1.95% | $5M | 65.0K |
| 26 | REGNRegeneron Pharmaceuticals Inchistory → | Cash Securities | 1.93% | $5M | 10.0K |
| 27 | VRTXCigna Corphistory → | Cash Securities | 1.75% | $4M | 25.0K |
| 28 | LLYIncyte Corphistory → | Cash Securities | 1.73% | $4M | 60.0K |
| 29 | S24Catalent Inchistory → | Cash Securities | 1.64% | $4M | 80.0K |
| 30 | HRCZimmer Biomet Holdings Inchistory → | Cash Securities | 1.60% | $4M | 40.0K |
| 31 | DexCom Inc | Cash Securities | 1.59% | $4M | 15.0K |
| 32 | BSXIntuitive Surgical Inchistory → | Cash Securities | 1.47% | $4M | 7.5K |
| 33 | TMOSmith & Nephew PLChistory → | Cash Securities | 1.42% | $4M | 100.0K |
| 34 | GRFSGrifols SAhistory → | Cash Securities | 1.39% | $4M | 175.0K |
| 35 | ABBVBio-Rad Laboratories Inchistory → | Cash Securities | 1.38% | $4M | 10.0K |
| 36 | BAXAnthem Inchistory → | Cash Securities | 1.34% | $3M | 15.0K |
| 37 | ZBHCharles River Laboratories In | Cash Securities | 1.00% | $3M | 20.0K |
| 38 | BMRNSelect Medical Holdings Corp | Cash Securities | 0.98% | $2M | 165.0K |
| 39 | THCSTERIS PLC | Cash Securities | 0.97% | $2M | 17.5K |
| 40 | STEPerrigo Co PLC | Cash Securities | 0.11% | $280,000 | 5.8K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.